Mutagenic and leukemogenic activity of haloperidol: a negative study.
The mutagenic and leukemogenic potential of haloperidol, a neuroleptic of the butyrophenone class, has been studied in an in vitro Ames Salmonella/microsome test and in an 18-month carcinogenicity study in mice. Three variants of the Salmonella mutation assay were included: the spot test, the standard plate incorporation test and the preincubation test. There was no evidence that haloperidol had any mutagenic activity in any of the Salmonella mutation tests with any of the Salmonella typhimurium tester strains in the presence or absence of Aroclor 1254-induced rat- or mouse-liver S9-mix. In the 18-month study, haloperidol was injected intraperitoneally as a solution (HaldolR) at a dosage of 5 mg/kg daily for 5, 10 and 20 consecutive days in 5-week-old mice. Leucocyte counts at several time points and histopathological tumor evaluation 18 months later did not reveal any leukemogenic or other carcinogenic effect. On the basis of these data, it may be concluded that haloperidol is not mutagenic in Salmonella nor leukemogenic in mice.
Janssen Pharmaceutica N.V., Department of Toxicology, Beerse, Belgium.
H
H
Van Cauteren
P
P
Vanparys
C
C
de Meester
M
M
Lambotte-Vandepaer
J
J
Vandenberghe
R
R
Marsboom
D000818:Animals; D006220:Haloperidol / Q000633:toxicity*; D007274:Injections, Intraperitoneal; D007942:Leukemia, Experimental / Q000139:chemically induced*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009152:Mutagenicity Tests / Q000379:methods; D009153:Mutagens
D009153:Mutagens; D006220:Haloperidol